Qunyi securities released a research report on January 26, saying that it maintained the buy rating of Chongqing Zhifei Biological Products Co.Ltd(300122) (300122.sz, latest price: 107.94 yuan). The reasons for rating mainly include: 1) the sales of HPV vaccine recovered in the second half of the year, and covid-19 vaccine developed overseas market; 2) The product pipeline is rich, and some independent products will gradually enter the harvest period. Risk warning: the listing progress of new products is less than expected; Covid-19 vaccine sales were lower than expected; Agent vaccine sales were less than expected.
AI comments: Chongqing Zhifei Biological Products Co.Ltd(300122) has received attention from 4 research reports of securities companies in recent month and bought 4.
